Sodium Picosulfate is a laxative medication used for colon cleansing before colonoscopy, acts by inhibiting absorption of water and electrolytes, and increasing their secretion. As a laxative medicine, it can also be used in the treatment of constipation. It stimulates the movement within the intestines which helps facilitate the passage of stool. It is also used with other medicines for bowel cleansing before colonoscopy or surgery. This medicine is available in different dosage forms like oral solution, tablet, syrup.
Physicochemical Properties
| Molecular Formula | C18H13NNA2O8S2 |
| Molecular Weight | 481.4 |
| Exact Mass | 480.9878 |
| CAS # | 10040-45-6 |
| PubChem CID | 68654 |
| Appearance | Typically exists as solid at room temperature |
| Melting Point | 272 - 275ºC |
| LogP | 4.101 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 31 |
| Complexity | 633 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S(=O)(=O)([O-])OC1C([H])=C([H])C(=C([H])C=1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=N1)C1C([H])=C([H])C(=C([H])C=1[H])OS(=O)(=O)[O-].[Na+].[Na+] |
| InChi Key | GOZDTZWAMGHLDY-UHFFFAOYSA-L |
| InChi Code | InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)/q2*+1/p-2 |
| Chemical Name | 4,4'-(2-Picolylidene)bis(phenylsulfuric acid) disodium salt |
| Synonyms | Sodium picosulphateSodium Picosulfate LA 391 Laxidogol Natrii picosulfas Picosulfate sodium Guttalax |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation ◉ Summary of Use during Lactation Sodium picosulfate is not absorbed from the gastrointestinal tract, and its active metabolite, which is absorbed, is not detectable in breastmilk. Sodium picosulfate can be taken during breastfeeding and no special precautions are required. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
| References |
[1].Toxicity study with sodium picosulfate in cultured liver cells of rabbit, rat and man. Arzneimittelforschung, 1981. 31(2): p. 321-5. [2].Effects of 'contact laxatives' on intestinal and colonic epithelial cell proliferation. Pharmacology, 1993. 47 Suppl 1: p. 187-95. [3].In vivo motility of rat colon chronically pretreated with sennosides. Pharmacology, 1993. 47 Suppl 1: p. 155-61. |
| Additional Infomation | Sodium picosulfate is an aryl sulfate and a member of pyridines. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~207.72 mM) H2O : ≥ 100 mg/mL (~207.72 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (207.72 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0773 mL | 10.3864 mL | 20.7727 mL | |
| 5 mM | 0.4155 mL | 2.0773 mL | 4.1545 mL | |
| 10 mM | 0.2077 mL | 1.0386 mL | 2.0773 mL |